MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b by Roscigno, Giuseppina et al.
Oncotarget580www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 1
MiR-221 promotes stemness of breast cancer cells by targeting 
DNMT3b
Giuseppina Roscigno1,2, Cristina Quintavalle1,2, Elvira Donnarumma3, Ilaria Puoti1, 
Angel Diaz-Lagares4, Margherita Iaboni1, Danilo Fiore1, Valentina Russo1, Matilde 
Todaro5, Giulia Romano6, Renato Thomas7, Giuseppina Cortino7, Miriam Gaggianesi5, 
Manel Esteller4, Carlo M. Croce6, Gerolama Condorelli1,2
1Department of Molecular Medicine and Medical Biotechnology, “Federico II” University of Naples, Naples, Italy
2IEOS-CNR, Naples, Italy
3IRCCS-SDN, Naples, Italy
4Epigenetic and Cancer Biology Program (PEBC) IDIBELL, Hospital Duran I Reynals, Barcelona, Spain
5 Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Laboratory, University of Palermo, 
Palermo, Italy
6 Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive 
Cancer Center, The Ohio State University, Columbus, OH, USA
7Department of Surgical and Oncology, Clinica Mediterranea, Naples, Italy
Correspondence to:
Gerolama Condorelli, e-mail: gecondor@unina.it
Keywords: microRNAs, breast cancer, cancer stem cells, DNMT
Received: June 15, 2015     Accepted: October 09, 2015     Published: October 19, 2015
ABSTRACT
Cancer stem cells (CSCs) are a small part of the heterogeneous tumor cell 
population possessing self-renewal and multilineage differentiation potential as well 
as a great ability to sustain tumorigenesis. The molecular pathways underlying CSC 
phenotype are not yet well characterized. MicroRNAs (miRs) are small noncoding 
RNAs that play a powerful role in biological processes. Early studies have linked 
miRs to the control of self-renewal and differentiation in normal and cancer stem 
cells. We aimed to study the functional role of miRs in human breast cancer stem 
cells (BCSCs), also named mammospheres. We found that miR-221 was upregulated 
in BCSCs compared to their differentiated counterpart. Similarly, mammospheres 
from T47D cells had an increased level of miR-221 compared to differentiated cells. 
Transfection of miR-221 in T47D cells increased the number of mammospheres and 
the expression of stem cell markers. Among miR-221’s targets, we identified DNMT3b. 
Furthermore, in BCSCs we found that DNMT3b repressed the expression of various 
stemness genes, such as Nanog and Oct 3/4, acting on the methylation of their 
promoters, partially reverting the effect of miR-221 on stemness. We hypothesize 
that miR-221 contributes to breast cancer tumorigenicity by regulating stemness, at 
least in part through the control of DNMT3b expression.
INTRODUCTION
Over the last years, evidence has accumulated on a 
small subclass of cancer cells with tumorigenic potential 
and stemness properties [1]. These so-called cancer stem 
cells (CSCs) have been isolated from a variety of tumor 
types, including those of the breast [2]. CSCs have two 
important characteristics: self-renewal and multipotency. 
These properties make CSCs able to generate new CSCs 
and simultaneously to produce differentiated mature cells 
responsible for the cellular heterogeneity of the tumor. 
CSCs are now considered the driving force of the tumor. In 
fact, they are the only cells able to regenerate a new tumor 
when xenografted in to mice, even when only very few 
cells are injected [2]. Furthermore, CSCs are resistant to 
conventional chemotherapy and are considered responsible 
for tumor recurrence [3]. Breast cancer stem cells (BCSCs) 
are characterized by high CD44 and low CD24 expression, 
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and can be identified as cells able to grow in suspension as 
spherical structures called mammospheres. Mammospheres 
derived from tissue specimens survive in non-adherent 
conditions and differentiate along different mammary 
epithelial lineages [4]. Within a tumor, CSC enrichment 
correlates with the grade of the tumor [5].
MicroRNAs (miRs) belong to the non-coding 
RNA family. They have a size ranging from 20 to 25 
nucleotides, and function as endogenous regulators of gene 
expression. MiRs impair mRNA translation or negatively 
regulate mRNA stability by recognizing complementary 
target sites in their 3′ untranslated region (UTR). MiRs 
are involved in the regulation of many physiological 
processes, including development, proliferation, and 
apoptosis, as well as of pathological processes such as 
cancerogenesis. In breast cancer, miR-21, -155, -96, and 
-182 have been identified as oncogenes [6–9], whereas 
miR-125, -205, and -206 have been identified as tumor 
suppressors [10–12]. MiRs play an essential role also in 
self-renewal of CSCs. For instance, miR-100 inhibited 
the maintenance and expansion of CSCs in basal-like 
breast cancer, and its ectopic expression enhanced BCSC 
differentiation, controlling the balance between self-
renewal and differentiation [13].
In the present study, we investigated whether other 
miRs are involved in the regulation of stemness in breast 
cancer. To this end, we isolated BCSCs from patients 
and analyzed their miR expression profile. We found 
that miR-221 was significantly up-regulated in BCSCs 
and was involved in stemness phenotyping through post-
transcriptional regulation of DNMT3b, a methyltransferase 
involved in epigenetic regulation of gene expression.
RESULTS
MiRs involved in stemness
To identify miRs differentially expressed in BCSCs 
and involved in stemness maintenance, we performed a 
microarray analysis. The array was performed analyzing 
the miR expression profile of BCSCs, collected from three 
patients, compared to that of breast cancer cells growing 
in adherence (differentiated cells). BCSCs obtained by 
biopsy digestion were characterized by real time PCR 
for the expression of the stem cells markers Nanog and 
Sox2 (Figure 1A) and by their ability to give rise tumors 
when injected into the flank of nude mice at low number 
(Supplementary Table S1). The microarray analysis revealed 
that there was a significant upregulation of miR-221, 
miR-24, and miR-29a in BCSCs and a down-regulation of 
miR-216a, miR-25, and let-7d compared to differentiated 
cells (Table 1). We focused our attention on miR-221, since 
its role in tumorigenesis has already been reported in several 
tumor types [14–16]. Microarray results for miR-221 were 
validated by real time PCR on the same samples and in one 
additional patient (patient #4) (Figure 1B).
T47D mammospheres are enriched in stem 
progenitors and expresses high levels of miR-221
We then studied in vitro enrichment and propagation 
of mammary stem cells with the T47D breast cancer cell 
line. 1 × 104 T47D cells were grown in DMEM-F12 
supplemented with EGF, b-FGF, and B27. After 7 
days of culture, we evaluated the stemness markers 
through real-time PCR and Western blot analysis, and 
the differentiation markers only through Western blot 
analysis. The stemness markers Nanog, Oct 3/4, Slug, 
and Zeb 1 were found upregulated in the suspension 
cultures, whereas the differentiation markers E-Cadherin, 
cytokeratin 18, and cytokeratin 8 were upregulated in 
adherence cultures (Figure 1C and 1D). Moreover, miR-
221 expression was increased in T47D mammospheres 
compared to differentiated cells (Figure 1E), highlighting 
the correlation of this miR with the stem cell state. Similar 
results were obtained in additional breast cancer cell lines 
(MCF-7, MDA-MB-231, and BT-549) (Supplementary 
Figure S1).
MiR-221 and stemness phenotype
To analyze the biological role of miR-221 for the 
stem cell phenotype, we overexpressed miR-221 in 
differentiated T47D cells and analyzed different stem 
cells markers. In order to obtain mammospheres, the cells 
were kept in stem medium for 6 days. We found that, 
compared to control, miR-221 overexpression induced 
a significant increase in the number of mammospheres 
(Figure 2A) and expression of stem cells markers Nanog, 
Oct 3/4, and β-Catenin (Figure 2B, 2C). Expression of 
anti-miR-221 induced an opposite effect (Figure 2D, 2E, 
2F). Similar results were obtained in the MCF-7 cell line 
(Supplementary Figure S2). To further investigate the 
effect of miR-221 on stem cell properties, we transduced 
T47D cells with a lentiviral construct encoding miR-
221. These stably overexpressing miR-221 cells showed 
enrichment of the CD44+/CD24− population thanks to an 
increase of CD44 (17% versus 43.7%) and to a decrease 
of CD24 (62.5% versus 33.8%), as assessed by FACS 
analysis (Figure 3A). The stable expression of miR-221 
in T47D cells induced also an increase in mammosphere 
number. This ability was enhanced after the first and 
second replanting, suggesting an expansion of the stem 
cell compartment (Figure 3B). The increase in sphere 
number and the upregulation of stemness markers upon 
miR-221 overexpression indicated an expansion of the 
stemness pool. In the same manner, the stable expression 
of miR-221, assessed by qRT-PCR in a breast primary cell 
line (patient #5), was able to increase sphere formation 
capacity and Nanog expression also in a primary context 
(Supplementary Figure S3A, S3B, S3C).
To further verify this phenotype, we assessed 
the shift from asymmetric to symmetric cell division 
with PKH26 staining. Fast and symmetrically dividing 
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Figure 1: MiR-221 expression in BCSCs and in T47D cell mammospheres. A. qRT-PCR validated the increase of stem markers 
Nanog and Sox 2 and B. of miR-221 in BCSCs. C, D. Nanog, Oct 3/4, Sox 2, Zeb 1, cytokeratin (Ck) 8 and cytokeratin (Ck) 18 were 
analyzed by qRT-PCR and Western blot and were found up-regulated in T47D stem cells compared to the differentiated counterpart. 
E. qRT-PCR revealed the upregulation of miR-221 in T47D mammospheres with respect to differentiated T47D cells. In C and E, data are 
mean values ± SD of three independent experiments. Significance was calculated using Student’s t-test. *, p < 0.05; **, p < 0.01. Western 
blots are from representative experiments.
Table 1: MiR expression in breast cancer stem cells
Unique ID Parametric p-value Fold Change (stem vs diff)
hsa- miR-221 0.013 1.8
hsa-miR-24 0.003 2.4
hsa-miR-29a 0.012 1.4
hsa-miR-216a 0.004 2.5
hsa-miR-25 0.042 2.2
let-7d 0.034 1.3
Up- and down-regulation of miRs in breast cancer stem cells vs differentiated cells. miR screening was performed in 
triplicate. A two-tailed, two sample t-test was used (p < 0.05). Four miRs were found significantly upregulated in breast 
cancer stem cells, and three were found downregulated.
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CSCs tend to rapidly lose PKH26, which then results 
equally distributed among the daughter cells during 
each cell division [5, 17]. Mammospheres from T47D 
cells stably transduced with a Tween control or with 
miR-221 were labeled with PKH26 and then analyzed 
by fluorescence microscopy and FACS after 7 days. 
As shown in Figure 3C, miR-221 overexpression 
induced a strong decrease of PKH26 (8.6% in Tween 
cells versus 1.5% in miR-221 cells), suggesting that 
miR-221 led to an expansion in stem cell number 
through symmetric division. Asymmetric division 
was evaluated by the distribution of the cell fate 
determinant Numb, known to be highly present upon 
differentiation, and of p53, whose expression is lost 
in stem cells [17, 18]. Western blotting revealed 
lower protein expression of both markers in miR-221-
overexpressing cells with respect to the Tween control 
(Figure 3D).
Stemness gene expression is mainly regulated by DNA 
methylation [19]. For this reason, we decided to evaluate the 
effect of miR-221 expression on DNA methylation levels of 
Nanog and Oct3/4 promoters and consequently the regulation 
of their expression profile. We assessed CpG dinucleotides, 
which are known to be methylated during differentiation 
[20, 21]. The 2 CpGs analyzed of Nanog promoter 
region were −83, −36 from to the Transcription Start Site 
(TSS); whereas the 3 CpGs analyzed of Oct 3/4 promoter 
region were +319, +346, +358 from the TSS. Through 
pyrosequencing analysis, we found that methylation levels 
at CpGs analyzed on Nanog and Oct 3/4 promoters were 
significant decreased (17% and 8% respectively) in cells 
transfected with miR-221 compared to the scrambled control 
(Figure 3E). Similar results were obtained in additional GpGs 
analyzed of both promoter regions (10% for CpG at −302, 
−300, −296 from TSS of Nanog and 10% for CpG + 250, 
+253, +277 of Oct 3/4.) (Supplementary Figure S4A).
Figure 2: MiR-221 effects on mammospheres and stemness genes expression. A. T47D cells were transfected with a pre-miR, 
and mammospheres counted after 6 days. miR-221 induced an increase in the number of mammospheres (140 ± SD versus 76 ± SD). 
B, C. Western blot and qRT-PCR showing that pre-miR-221 transfected in T47D cells upregulates stem cell marker expression. Anti-
miR-221 transfection induced a reduction of mammospheres (48 ± SD versus 60 ± SD) D. and of stem cell markers E, F. Western blots 
are representative experiments. Data are mean values ± SD of three independent experiments. In A, D, significance was calculated using 
Student’s t-test. *, p < 0.05.
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MiR-221 specifically represses DNMT3b 
expression
Thereafter, we investigated miR-221 targets 
possibly involved in stemness. Among the potential targets 
predicted by bioinformatics (RNA hybrid- http://www.
microRNA.org/, Miranda- http://www.microRNA.org/), 
we focus our attention on DNMT3b, which encodes a DNA 
methyltransferase involved in de novo DNA methylation 
[22–24]. To examine whether miR-221 interfered with 
DNMT3b expression by directly targeting the predicted 
3′UTR region, we cloned this region downstream of a 
luciferase reporter gene in the pGL3 vector. HEK-293 
cells are an easy model to use for the luciferase assay 
thanks to their transfection efficiency. HEK-293 cells were 
transfected with the reporter plasmid in the presence of 
a negative control miR (scrambled miR) or miR-221. As 
shown in Figure 4A, DNMT3b 3′UTR luciferase reporter 
activity was significantly repressed by the addition of miR-
221 compared to the scrambled sequence. This luciferase 
activity was not affected by miR-221 overexpression 
in the presence of a mutant construct in which the seed 
sequence was cloned inversely (Figure 4A). In order to 
find a causative effect between miR-221 and DNMT3b 
expression, we transfected T47D cells with a pre-miR-221 
for 48 h and then analyzed DNMT3b levels by Western 
blot and qRT-PCR. We found that DNMT3b protein 
and mRNA levels were downregulated after miR-221 
overexpression (Figure 4B). Similar results were obtained 
when we transfected miR-222, which shares a similar seed 
Figure 3: MiR-221 overexpression regulates stemness properties in BCSCs. A. FACS analysis of CD24/CD44 expression 
in T47D cells infected with miR-221 lentivirus and control Tween virus (Tw). MiR-221 stable expression induced an increase of CD44 
(17% versus 43.7%) and a decrease of CD24 (62.5% versus 33.8%). B. Effect of lentivirally mediated overexpression of miR-221 on 
mammosphere number at the first plating and after dissociation and replating. The data represent the mean value ± SD of two independent 
experiments. C. T47D mammospheres stably infected with the empty vector or miR-221 were evaluated by FACS for PKH26 staining. 
miR-221 infection induced a decrease of PKH26 in cells (8.6% versus 1.5%). The staining of the two populations was verified at day 0 or 
after 6 days, as indicated in C. D. Asymmetric division was evaluated by Western blotting for Numb and p53. Western blots is representative 
experiment. E. Analysis of methylation change of two consecutive CpGs of Nanog and 3 CpGs of Oct 3/4 promoters (17% and 8% 
respectively). Methylation values: mean of consecutive CpGs. Significance was calculated using U-Mann Whitney test. *, p < 0.05.
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sequence with miR-221 (Supplementary Figure S5). In 
contrast, anti-miR-221 induced an increase of DNMT3b 
levels (Figure 4C). Then, we verified DNMT3b expression 
in stem and differentiated T47D cells. As shown in Figure 
4D, DNMT3b expression was lower in stem cells and 
inversely correlated with miR-221 levels. Furthermore, 
DNMT3b expression was reduced in T47D cells 
transfected with miR-221 lentiviral vectors (Figure 4E). 
We also observed a reduction of DNMT3b levels by qRT-
PCR and immunofluorescence in stem cells compared to 
differentiated primary cells (Figure 5A, 5C), as well as in 
MCF7 cells and MDA-MB-231 cells (Figure 5B).
miR-221 controls stemness by inhibiting 
DNMT3b expression
DNMT3b is a master regulator of Nanog and Oct 3/4 
expression and, through its methylation activity, represses 
their expression during embryogenesis [25]. Therefore, 
we wondered whether the stemness features observed 
upon expression of miR-221 were related to DNMT3b 
downregulation and, consequently, to a reduced methylation 
activity. We transfected T47D cells with a DNMT3b cDNA 
and investigated the effect on stem marker expression and 
mammosphere formation. As shown in Figure 6A–6B 
DNMT3b inhibited mammosphere formation (63 versus 80) 
and Nanog, and Oct 3/4 expression. In contrast, treatment 
with a specific si-DNMT3b-mRNA induced an increase in 
mammosphere number (Figure 6D) and upregulated Nanog 
and Oct 3/4 protein levels (Figure 6E). Furthermore, to 
establish a causal link between miR-221-mediated DNMT3b 
downregulation and stem cell phenotype, we performed a 
rescue experiment by transfecting T47D cells simultaneously 
with pre-miR-221 and a DNMT3b cDNA lacking the 3′UTR. 
We found that the effect of miR-221 on Nanog and Oct 3/4 
expression was abolished by DNMT3b cDNA overexpression 
Figure 4: DNMT3b is a direct target of miR-221. A. Predicted alignment between the miR-221 sequence and the 3′UTR of DNMT3b. 
Luciferase assay showed that reporter activity was inhibited in T47D cells only in the presence of wild type DNMT3b and not with a mutated 
3′UTR. The data represent the results of two independent experiments. B. MiR-221 transfection downregulated DNMT3b mRNA and protein 
levels, as assessed by qRT-PCR and Western blotting. C. Anti-miR-221 transfection upregulated the levels of DNMT3b. D. DNMT3b mRNA 
and protein were downregulated in T47D stem cells compared to differentiated cells. E. DNMT3b mRNA and protein were downregulated 
in T47D cells stably infected with a miR-221 lentivirus. In B, C, D, E data are mean values ± SD from three independent experiments. 
Significance was calculated using Student’s t-test. *, p < 0.05; **, p < 0.01. Western blot analyses are from representative experiments.
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(Figure 6B). Its effect on the number of mammospheres (114 
versus 93) (Figure 6A) and on growth in soft agar was also 
partially reverted (Figure 6C). To further asses the role of 
DNMT3b, we evaluated mammosphere number in T47D 
cells stably transfected with a shRNA targeting DNMT3b. 
The expression of a DNMT3b short hairpin increased the 
number of mammospheres in DNMT3b-silenced T47D cells, 
an effect enhanced after the first replating (Figure 6F).
We then hypothesized that DNMT3b affects the 
methylation pattern of Nanog and Oct 3/4 promoter 
regions, influencing their expression. Pyrosequencing 
analysis revealed that cells transfected with a DNMT3b 
siRNA showed a significant decrease (23% and 11%, 
respectively) in methylation levels at CpGs analyzed on 
Nanog and Oct 3/4 promoters compared to the scrambled 
control cells (Figure 6G). Similar results were obtained in 
additional GpGs analyzed of both promoter regions (20% 
and 5% respectively) (Supplementary Figure S4B).
DISCUSSION
Breast cancer is the leading cause of death in woman 
and is characterized by an elevated heterogeneity, different 
responses to therapy, and metastatic variability among 
patients [26]. It represents the first human carcinoma 
for which a putative cancer stem cell subpopulation 
has been isolated on the basis of its CD44+/CD24−/low 
antigenic phenotype [2]. However, little is known on the 
mechanisms regulating the ability of BCSCs for self-
renewal and to initiate tumors.
Recently, miRs have been found to be critical 
regulators of several cellular events [27]. By their 
ability to target hundreds of mRNAs, they can induce a 
rapid switch in cell fate and a fine exchange in genome 
expression; they are now accepted as major post-
transcriptional regulators. The importance of miRs in 
gene expression regulation is emphasized by the finding 
that they are often deregulated in cancer [28]. MiRs may 
affect cancer development, progression, and response to 
therapy. Interestingly, some miRs have been reported to 
regulate CSC phenotype, since their modulation has been 
shown to contribute to the maintenance or triggering of the 
phenotype in different cancer models. For instance, it was 
found that miR-22 induces an expansion of the breast CSC 
compartment and induces metastasis by downregulating a 
member of the TET family [29]. Different members of the 
Figure 5: DNMT3b expression in stem and differentiated breast cancer cells. A. DNMT3b levels were analyzed by qRT-PCR 
in stem and differentiated breast cancer primary cells or B. in MCF7 cells and MDA-231 cells. C. Immunofluorecence analysis of DNMT3b 
expression in stem and differentiated breast cancer primary cells from 4 patients. In B, data are mean values ± SD from three independent 
experiments. Significance was calculated using Student’s t-test. *, p < 0.05; **, p < 0.01.
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miR-200 family were found downregulated in CSCs 
isolated from colorectal, head and neck, prostate, and 
breast cancer compared to their non-CSC counterparts 
[30–33]. Expression of miR-200 represses EMT, contri-
buting thus to the progression of cancer by promoting 
invasion, metastasis [34], and stemness phenotype.
In the present study, we identify miR-221 as an 
important player in the control of the CSC homeostasis. 
We provide evidence that miR-221 is expressed at higher 
levels in the stem cell population of primary and T47D 
cells compared to differentiated cells. MiR-221 has been 
found overexpressed in a number of human tumors by us 
and others [14, 35–38]. The relevance of this miR as an 
oncogene in breast cancer is reported by several papers, 
demonstrating the broad spectrum of action miR-221 and 
its regulation of several features of tumorigenesis [35, 39]. 
MiR-221 is found often abnormally expressed in breast 
cancer [40] and recent studies have found that it may be 
responsible for resistance to tamoxifene [41]. MiR-221 
promotes tumorigenesis of triple negative breast cancer 
through the alteration of key genes of the EMT process, 
such as E-cadherin, Slug, and Snail [42]; its expression is 
under the direct control of Slug, suggesting the existence 
of a miR-221–EMT regulatory loop [43]. In addition, it 
was reported that miR-221 is upregulated in prolonged 
mammosphere cultures of MCF7 cells undergoing EMT 
and with downregulated ER-alpha [44], and that it is able 
to sustain breast cell hierarchy in normal and malignant 
breast cells, probably via EMT [45].
Here we demonstrate that miR-221 induces 
expression of pluripotency-associated genes, such as 
Nanog, Oct 3/4, and β—Catenin, enforcing stemness 
and mammosphere formation. miR-221 downregulates 
DNMT3b expression, modifying BCSC phenotype. 
Figure 6: MiR-221 regulates stemness by targeting DNMT3b. A. DNMT3b represses mammosphere formation, as assessed 
with a mammosphere counting assay. Data are mean values ± SD from three independent experiments. Significance was calculated using 
Student’s t-test. *, p < 0.05. B. Stem cell markers assessed by Western blotting. C. MiR-221 transfection in T47 stem cells induced an 
increase in the number of colonies, as assessed by a soft agar assay. Co-transfection of DNMT3b and miR-221 rescued this effect. Data are 
mean values ± SD from two independent experiments. Significance was calculated using Student’s t-test.**, p < 0.01; Transient DNMT3 
silencing mimicked the effect of miR-221 on D. sphere formation and E. stem markers, whereas stable silencing mimicked miR-221 
behavior F. on sphere number in a plating assay. In D, data are mean values ± SD of three independent experiments. Significance was 
calculated using Student’s t-test. *, p < 0.05. In G. Pyrosequencing analysis of cells transfected with a DNMT3b siRNA showed a significant 
decrease in methylation levels at CpGs analyzed on Nanog and Oct 3/4 promoters compared to the scrambled control cells (23% and 11% 
respectively). Significance was calculated using U-Mann Whitney test. *, p < 0.05. Western blot analyses are representative experiments.
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DNMT3a, DNMT3b, and DNMT1 are members of the 
DNA methylation machinery. During DNA replication, 
DNMT1 recognizes the CpGs present on the parent strand 
and methylates the corresponding CpG sites of the newly 
synthesized strand [46, 47]. In contrast, DNMT3a and 
DNMT3b are responsible for de novo DNA methylation 
predominantly during early development [48, 49]; in 
addition, they are important for stable inheritance of some 
DNA methylation, and the silencing of both enzymes in 
embryonic stem cells (ESCs) determines a progressive loss 
of DNA methylation at critical sites of the genome, such as 
repetitive and single copy elements [50]. Moreover, ESCs 
lacking both DNMT3a and DNMT3b progressively lose 
differentiation potential after several cell passages, but are 
able to maintain self-renewal [25, 50, 51]. Interestingly, 
it has been demonstrated that DNMT3a and DNMT3b 
ablation induces aberrant expression of Nanog and 
Oct 3/4 in ESCs [52]. The role of DNMT3b in cancer 
development is not still clear. Although DNMT3b was 
classically considered an oncogene, due to its role in the 
hypermethylation of tumor suppressor genes during tumor 
progression in lung, breast, colon, and bladder cancers 
[53, 54], several reports also indicate a tumor suppressor 
behavior at an advanced tumor stage [55, 56]. Therefore, 
DNMT3b may act as a tumor suppressor or an oncogene 
depending on tumor stage or on the type of tumor cell 
population. In the present study, we demonstrate that 
DNMT3b represses the expression of Nanog and Oct 3/4 
and increases the number of breast cancer cell spheres. 
Thus, DNMT3b downregulation may represent an 
advantage for cancer development, driving the expansion 
of the stem cell compartment. Further experiments are 
necessary to elucidate the mechanism through which 
DNMT3b regulates stemness, other than acting directly 
on Nanog and Oct 3/4 promoters.
In conclusion, we have identified a new mechanism 
by which miR-221 affects the tumor stemness phenotype 
of breast cancer cells, providing more information on the 
oncogenic role of miR-221 in breast cancer.
MATERIALS AND METHODS
Cell and mammosphere culture
Differentiated breast tumor cells from three patients 
(#1, #2, #3) and BTSCs (breast tumor stem cells) were 
obtained as previously described [57] and were used for 
microRNA array. T47D cells were grown in RPMI 1640 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 2 mM L-glutamine, and 100 U/ml penicillin/
streptomycin. For mammosphere culture, single cells 
were plated at a density of 1,000 cells/ml. Cells were 
grown in serum-free DMEM-F12 (Sigma, Milan, Italy) 
supplemented with B27 (Life technologies Milan Italy), 
10 ng/ml EGF (Sigma, Milan, Italy), 20 ng/ml βFGF (BD 
Biosciences, Milan, Italy), and 1X antibiotic–antimycotics 
(Life technologies, Milan, Italy). After 5–7 days, 
mammospheres, which appeared as spheres of floating 
viable cells, were collected by gentle centrifugation 
(800 rpm) and dissociated with 0.25% trypsin for 5 min. 
HEK-293 cells were grown in DMEM supplemented 
with 10% heat-inactivated FBS and 100 U/ml penicillin/
streptomycin.
Cell and sphere transfection
For transient transfection with miRs, cells at 50% 
confluence were transfected using Oligofectamine (Life 
Technologies Milan Italy) with 100 nM of pre-miR-221, 
scrambled, or anti miR-221 (Ambion, Life Technologies 
Milan Italy). In order to overexpress DNMT3b, cells 
were transfected with Lipofectamine 2000 and 3 μg of 
DNMT3b cDNA, a kind gift of Ana Portela (IDIBELL, 
Barcelona, Spain). To transiently knockdown DNMT3b 
gene expression, a pool of DNMT3b siRNAs is transfected 
using Lipopfectamine 2000 at a final concentration of 
100 nM (Santa Cruz Biotechnology, MA, USA). To 
stably knockdown DNMT3b, cells were infected with a 
shDNMT3b (Santa Cruz Biotechnology, MA, USA) and 
the expression of DNMT3b studied by qRT-PCR in pooled 
cell populations (data not shown).
Transduction with viral vectors
T47D cells and a primary breast cell line obtained 
from patient #5 were infected using Tween miR-221 or 
Tween control vector, as already described by Quintavalle 
et al. [14]. Briefly, on the day of infection, the medium 
was removed and replaced with viral supernatant with the 
addition of 4 mg/ml of polybrene (Sigma Aldrich, Milan 
Italy). Cells were then centrifuged in their plate for 45 
min in a Beckman GS-6KR centrifuge, at 1800 rpm and 
32°C. After centrifugation, cells were kept overnight in 
a 5% CO2 incubator at 37°C. After exposure, cells were 
washed twice with cold PBS and fresh medium added. 
48 h after the transduction, cells were washed with PBS, 
harvested with trypsin/EDTA, and analyzed by FACS for 
GFP expression.
Protein isolation and western blotting
Cells were washed twice in ice-cold PBS, and lysed 
in JS buffer (50 mM HEPES pH 7.5 containing 150 mM 
NaCl, 1% Glycerol, 1% Triton X100, 1.5 mM MgCl2, 
5 mM EGTA, 1 mM Na3VO4, and 1X protease inhibitor 
cocktail). Protein concentration was determined by the 
Bradford assay (BioRad, Milan, Italy) using bovine serum 
albumin as the standard, and equal amounts of proteins 
were analyzed by SDS-PAGE (12.5% acrylamide). Gels 
were electroblotted onto nitrocellulose membranes (G&E 
Healthcare, Milan, Italy). Membranes were blocked for 
1 h with 5% non-fat dry milk in Tris Buffered Saline 
(TBS) containing 0.1% Tween-20, and incubated at 
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4°C overnight with the primary antibody. Detection 
was performed with peroxidase-conjugated secondary 
antibodies using an enhanced chemiluminescence system 
(ThermoEuroclone, Milan, Italy). Primary antibodies used 
were: anti-Zeb-1, -Oct 3/4, -Nanog, -cytokeratin 18, and 
-cytokeratin 8 (Santa Cruz Biotechnologies, MA, USA), 
anti-DNMT3b (Abcam, MA, USA), and anti-β-actin 
(Sigma Aldrich, Milan, Italy).
miRNA microarray
5 μg of total RNA from each sample was reverse 
transcribed using biotin end-labeled random-Octamer 
oligonucleotide primer. Hybridization of biotin-labeled 
complementary DNA was performed on Ohio State 
University custom miRNA microarray chips (OSU_
CCC version 3.0), which contain 1150 miR probes, 
including 326 human and 249 mouse miR genes, spotted 
in duplicate. The hybridized chips were washed and 
processed to detect biotin-containing transcripts by 
streptavidin-Alexa647 conjugate and scanned on an Axon 
4000B microarray scanner (Axon Instruments, Sunnyvale, 
California, USA).
Raw data were normalized and analyzed with 
GENESPRING 7.2 software (zcomSilicon Genetics, 
Redwood City, CA, USA). Expression data were median-
centered with the GENESPRING normalization option and 
the global median normalization of the BIOCONDUCTOR 
package (http://www.bioconductor.org), which produced 
similar results. Statistical comparisons were done with 
the GENESPRING ANOVA tool, predictive analysis 
of microarray (PAM), and the Significance Analysis of 
Microarray (SAM) software (http://www-stat.stanford.
edu/~tibs/SAM/index.html).
Mammosphere forming assay
Mammospheres were resuspended in 0.5% agar 
(Bacto-Agar, Difco Laboratories) and layered on a 
preformed 0.8% agar layer using 60 mm Petri dishes (BD). 
Colonies were counted under an inverted microscope 
(Nikon, Milan, Italy) and then photographed.
RNA extraction and real-time PCR
Total RNAs (miR and mRNA) were extracted 
using Trizol (LifeTechnologies, Milan, Italy) according 
to the manufacturer’s protocol. Reverse transcription 
of total miRNA was performed using miScript reverse 
Transcription Kit (Qiagen, Milan Italy), for mRNA 
we used SuperScript® III Reverse Transcriptase (Life 
Technologies, Milan, Italy). Quantitative analysis of 
Nanog, Oct 3/4, Sox2, β-Actin (as an internal reference), 
miR-221, and RNU6B (as an internal reference) was 
performed by real time PCR using specific primers 
(Qiagen, Milan, Italy), miScript SYBR Green PCR Kit 
(Qiagen, Milan Italy), and iQ™ SYBR Green Supermix 
(Bio-Rad, Milan, Italy), respectively. Experiments were 
carried out in triplicate for each data point, and data 
analysis was performed with software (Bio-Rad, Milan 
Italy).
Luciferase assay
The 3′ UTR of the human DNMT3b gene was PCR-
amplified using the following primers: DNMT3b-Fw:5′G
CTCTAGACAGCCAGGCCCCAAGCCC3′; DNMT3b-
Rv: 5′GCTCTAGAACCTCAGGCTACCCCTGC3′, 
and cloned downstream of the Renilla luciferase stop 
codon in pGL3 control vector (Promega, Milan, Italy). 
An inverted sequence of the miR-binding sites was used 
as negative control. HEK-293 cells were co-transfected 
with 1.2 μg of plasmid and 400 μg of a Renilla luciferase 
expression construct, pRL-TK (Promega, Milan, Italy), 
with Lipofectamine 2000 (Life Technologies, Milan, 
Italy). Cells were harvested 24 h post-transfection and 
assayed with Dual Luciferase Assay (Promega, Milan, 
Italy) according to the manufacturer’s instructions. Three 
independent experiments were performed in triplicate.
DNA methylation analysis by pyrosequencing
Bisulphite conversion of 500 ng of each DNA 
sample was performed with EZ DNA Methylation-
Gold Kit (Zymo Research, Milan Italy) according to 
the manufacturer’s recommendations. PCR for Nanog 
and Oct 3/4 promoters was performed with 1 μl of 
bisulphite converted DNA under standard conditions 
with biotinylated primers using an annealing temperature 
of 60°C. Primer sequences are given in Supplementary 
Table S2 and were designed with PyroMark Assay Design 
2.0. PCR products were observed on 2% agarose gels 
before pyrosequencing analysis. Reactions were performed 
in a PyroMark Q96 System version 2.0.6 (Qiagen, Milan, 
Italy) and the methylation values of the CpG dinucleotides 
were obtained using Pyro Q-CpG 1.0.9 (Qiagen, Milan, 
Italy). The 2 CpGs analyzed of Nanog promoter region 
were −83, −36, from to the Transcription Start Site (TSS); 
whereas the 3 CpGs analyzed of Oct3/4 promoter region 
were +319, +346, +358 from the TSS. Additional GpGs 
analyzed of both promoter regions were −302, −300, −296 
from TSS of Nanog and + 250, +253, +277 from TSS 
of Oct 3/4.
Immunofluorescence
Immunofluorescence was performed on cultured 
BCSC cytospins fixed with 2% paraformaldehyde for 20 
minutes at 37°C, washed and permeabilized with PBS plus 
0.1% Triton X-100 for 10 min on ice. After washing, cells 
were stained overnight at 4°C using antibodies against 
DNMT3b (Abcam- ab13604) or isotype-matched controls 
at appropriate dilutions. Then cells were labeled with 
FITC-conjugated secondary antibodies for 1 h at 37°C. 
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Nucleus counterstaining was performed using Toto-3 
iodide. Samples were analyzed by confocal microscope.
Statistical analysis
All experiments were repeated at least twice. 
Continuous variables are given as mean ± 1 standard 
deviation (SD). For two-group comparison, Student’s 
t-test was used to determine differences between mean 
values for normal distribution. All data were analyzed for 
significance using GraphPadPrism 6 software (San Diego, 
CA, USA); a probability level <0.05 was considered 
significant throughout the analysis.
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